
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lead Product(s) : Doxcercalciferol
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Doxercalciferol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperparathyroidism, Secondary-associated with Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2016
Lead Product(s) : Doxcercalciferol
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
 Reset All
Reset All


 Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.